reports
Immune Pharmaceuticals Files for Chapter 11 Protection
Immune Pharmaceuticals Files for Chapter 11 Protection FORT LEE, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, has filed for chapter 11 bankruptcy in the Federal Bankruptcy Court in New Jersey. Despite making significant progress towards a bertilimumab strategic transaction, with the partnering process already yielding term sheets, Immune was unable to negotiate terms for additional funding to provide the several month’s run...
Immune Pharmaceuticals Engages Extera Partners to Pursue Bertilimumab ...
Immune Pharmaceuticals Engages Extera Partners to Pursue Bertilimumab Strategic Transaction FORT LEE, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or “the Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that it has engaged Extera Partners to lead the Company’s ongoing effort to secure a partnership for bertilimumab, a phase 2, first-in-class, fully human anti-eotaxin-1 monoclonal antibody. Tony Fiorino, MD, PhD, Immune’s interim Chief Executive Officer, stated, “The ...
UPDATE -- Immune Pharmaceuticals Announces Adjournment of Special Meet...
UPDATE -- Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders Meeting adjourned in order to gather additional votes FORT LEE, N.J., Dec. 06, 2018 (GLOBE NEWSWIRE) -- (OTCQB; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that its Special Meeting of Stockholders, held on December 5, 2018, was adjourned until December 19, 2018, at 9:30 a.m. Eastern Time. The Adjourned Meeting will be held at the offices of the Company’s counsel, Lowenst...
Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement f...
Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights Immune Receives $500,000 for Option; If Exercised, Total Deal Value Could Exceed $17.5 Million FORT LEE, N.J. and NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, and (“Vector”), a biopharmaceutical company acquiring, developing and commercializing oncology therapeutics, today announced the execution of an agreement that gives Vector an option t...
Immune Pharmaceuticals Reschedules Corporate Update Call
Immune Pharmaceuticals Reschedules Corporate Update Call Conference call with live audio webcast rescheduled until Tuesday, November 27th at 8:30 am ET FORT LEE, N.J., Nov. 19, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, is delaying its corporate call until after the holiday week in order to provide a more comprehensive shareholder update. The call will now take place on Tuesday, November 27 at 8:30 am Eastern Time. CONFERENCE CALL AND WEB...
Immune Pharmaceuticals Schedules Corporate Update Call
Immune Pharmaceuticals Schedules Corporate Update Call Conference call with live audio webcast on Tuesday, November 20th at 8:30 am ET FORT LEE, N.J., Nov. 16, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, will provide a corporate update on Tuesday, November 20 at 8:30 am Eastern Time. On the call, Tony Fiorino, interim Chief Executive Officer of Immune, will provide an update on various corporate matters, including the bertilimumab clinic...
New Clinical Data Support Bertilimumab Activity in Bullous Pemphigoid
New Clinical Data Support Bertilimumab Activity in Bullous Pemphigoid No anti-drug antibodies observed and multidose pharmacokinetics as expected FORT LEE, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today released additional results from its positive, proof-of-concept phase 2a trial of bertilimumab in bullous pemphigoid. These results include pharmacokinetic (PK), pharmacodynamic (PD) and anti-drug antibody data. The key ob...
Immune Pharmaceuticals Announces Positive Preclinical Results in Asthm...
Immune Pharmaceuticals Announces Positive Preclinical Results in Asthma A broad anti-inflammatory effect observed FORT LEE, N.J., Oct. 17, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today positive results from a mouse study demonstrating that blockade of eotaxin-1 reduces lung inflammation and has a broader inhibitory effect on inflammatory cells than does blockade of interleukin (IL)-5. In a moue model of asthma, a monoclona...
Immune Pharmaceuticals Announces $5 Million Financing
Immune Pharmaceuticals Announces $5 Million Financing Company to launch bertilimumab partnering process in the current quarter FORT LEE, N.J., Oct. 10, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has entered into a Securities Purchase Agreement with an institutional investor in which it has sold $5.5 million in principal amount of Senior Secured Redeemable Convertible Debentures (the “Debentures”) for $2 million in ca...
Immune Pharmaceuticals Provides a Corporate Update
Immune Pharmaceuticals Provides a Corporate Update Conference call with live audio webcast today, Thursday, September 13th at 8:30am EDT FORT LEE, N.J., Sept. 13, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today provided a corporate update. “There have been many positive developments at Immune during this time of transition,” stated interim Chief Executive Officer Tony Fiorino, MD, PhD. “The recent regulatory successes for bertilimumab un...
Bertilimumab Granted Fast Track Designation for the Treatment of Bullo...
Bertilimumab Granted Fast Track Designation for the Treatment of Bullous Pemphigoid Company to provide corporate update during conference call with live audio webcast on Thursday, September 13th at 8:30am EDT FORT LEE, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to bertilimumab for the treatment of bullous pemphigoid. “I am tr...
Immune Pharmaceuticals Issues Statement on Former Chief Executive Offi...
Immune Pharmaceuticals Issues Statement on Former Chief Executive Officer FORT LEE, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today commented on a complaint filed by the Securities and Exchange Commission (the “SEC”) on September 8, 2018 in the United States District Court for the Southern District of New York against a number of individuals and entities, including the Company’s former Chief Execu...
Bertilimumab Granted Orphan Drug Designation for the Treatment of Bull...
Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid ENGLEWOOD CLIFFS, N.J., Aug. 20, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to bertilimumab for the treatment of bullous pemphigoid (BP). “We are incredibly gratified that bertilimumab has received Orphan Drug Designation for the treatment of bullous p...
Immune Pharmaceuticals Postpones Special Meeting of Stockholders
Immune Pharmaceuticals Postpones Special Meeting of Stockholders - Special Meeting of Stockholders scheduled for August 22, 2018 postponed - - Company plans to appeal Nasdaq delisting determination - ENGLEWOOD CLIFFS, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it is postponing its Special Meeting of Stockholders scheduled for August 22, 2018, which was called for the purpose of considering and voting on ...
Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Desig...
Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for Bertilimumab for the Treatment of Bullous Pemphigoid ENGLEWOOD CLIFFS, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the Company’s application for Orphan Drug Designation for bertilimuma...
Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligib...
Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018 ENGLEWOOD CLIFFS, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- (Nasdaq:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") indicating that Nasdaq has determined to delist the Company's shares from The Nasdaq Capital Market due to the Company’s non-compliance with the minimum b...
Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse...
Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split – Immune to hold Special Meeting of Stockholders Wednesday, August 22, 2018 – – Company encourages stockholders to vote in favor of the Board of Director’s suggested proposals – ENGLEWOOD CLIFFS, July 17, 2018 (GLOBE NEWSWIRE) -- (Nasdaq:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today it has filed a definitive proxy statement with the Securities and Exchange Commission ("SEC") an...
WuXi Biologics and Immune Pharmaceuticals Announce Late-phase Developm...
WuXi Biologics and Immune Pharmaceuticals Announce Late-phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody SHANGHAI, China and ENGLEWOOD CLIFFS, N.J., July 09, 2018 (GLOBE NEWSWIRE) -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Immune Pharmaceuticals (Nasdaq:IMNP) (“Immune”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced ...
Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determinati...
Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination Company to Request Hearing ENGLEWOOD CLIFFS, N.J., June 08, 2018 (GLOBE NEWSWIRE) -- (Nasdaq:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it received a letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market, Inc. ("Nasdaq") indicating that the Company's failure to regain compliance with the minimum $1.00 bid price requirement by May 30, 2018, cou...
- GlobalData Department
Immune Pharmaceuticals Inc (IMNP) - Medical Equipment - Deals and Alli...
Summary Immune Pharmaceuticals Inc (Immune Pharma), formerly EpiCept Corp is a biotechnology company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and cancer. The company's bertilimumab is under clinical development for moderate to severe ulcerative colitis, crohn's disease and bullous pemphigoid. It also offers nanomabs, which is an antibody nanoparticle conjugate technology platform for the targeted delivery of chemotherapeutics. Immune Pharma’...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.